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Abstract
Purpose MRPS23 is recognized as a driver of proliferation in luminal breast cancer. The aims of the present study were to 
describe MRPS23 copy number change in breast cancer, and to assess associations between MRPS23 copy number change and 
molecular subtype, proliferation and prognosis, and between MRPS23 gene expression and molecular subtype and prognosis.
Methods Using fluorescence in situ hybridization (FISH), we examined MRPS23 and centromere 17 copy number in 590 
formalin-fixed, paraffin-embedded primary tumours and 144 corresponding lymph node metastases from a cohort of Nor-
wegian breast cancer patients. Furthermore, we analysed MRPS23 gene expression data in 1971 primary breast cancer 
tumours from the METABRIC dataset. We used Pearson’s χ2 test to assess associations between MRPS23 copy number 
and molecular subtype and proliferation, and between MRPS23 expression and molecular subtype. We studied prognosis 
by estimating hazard ratios and cumulative incidence of death from breast cancer according to MRPS23 copy number and 
MRPS23 expression status.
Results We found MRPS23 amplification (mean MRPS23 copy number ≥ 6 and/or MRPS23/chromosome 17 ratio ≥ 2) in 8% 
of primary tumours. Copy number increase associated with non-basal subtypes and higher tumour cell proliferation (Ki67). 
Higher MRPS23 expression associated with the Luminal B subtype. We found no significant association between MRPS23 
amplification or MRSP23 gene expression, and prognosis.
Conclusion Amplification of MRPS23 is associated with higher proliferation and non-basal subtypes in breast cancer. High 
MRPS23 expression is associated with the Luminal B subtype.
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Introduction
Increased proliferation is a hallmark of cancer [1, 2], and 
identification of genetic drivers of proliferation could be 
important for prognostication and development of new 
targeted treatment. By high-throughput genomic analy-
ses, Gatza et  al. identified proliferation driving genes 
in non-basal breast cancer [3]. Amplification of four of 
these genes (MRPS23, FGD5, DTX3 and METTL6) was 
associated with a poor prognosis. Mitochondrial riboso-
mal protein S23 (MRPS23) is located on the long arm of 
chromosome 17 (17q22) and belongs to the mitochondrial 
ribosomal protein gene family [4, 5]. Mitochondrial ribo-
somes are composed of a small 28S subunit and a large 
39S subunit. MRPS23 encodes the 28S subunit [4, 5]. High 
MRPS23 expression has been found in colon [6], cervi-
cal [7, 8] and hepatocellular cancer [9, 10], and associ-
ated with poor prognosis in non-basal breast cancer [3], 
hepatocellular [10] and cervical cancer [7, 8]. In a breast 
cancer mouse model, MRPS23 knock-down reduced pro-
liferation, induced apoptosis and limited angiogenesis and 
lymph node metastasis [11].
Our group has previously reclassified breast cancer 
tumours from a large cohort of Norwegian women into 
six molecular subtypes based on immunohistochemis-
try (IHC) and chromogenic in situ hybridization (CISH) 
[12]. The aims of the present study were to characterize 
MRPS23 copy number alterations by fluorescence in situ 
hybridization (FISH) on formalin-fixed, paraffin-embed-
ded (FFPE) primary tumour tissue and corresponding 
lymph node metastases from this cohort, and to assess how 
these copy number alterations associates with molecular 
subtypes, proliferation and prognosis. Furthermore, using 
the METABRIC dataset [13], we assess how MRPS23 gene 
expression levels correlate with molecular subtypes and 
prognosis.
Materials and methods
Study populations and specimen characteristics
Cohort 1
Between 1956 and 1959, 25,727 women born 1886–1928 
were invited to attend a clinical examination for early 
detection of breast cancer in Nord-Trøndelag County, 
Norway [14]. Through linkage with data from the Can-
cer Registry of Norway, these women were followed for 
breast cancer occurrence. Between 1961 and 2008, 1393 
new breast cancers were registered. All tumours were 
reclassified according to histological type and grade [12, 
15]. Tissue microarray (TMA) blocks were made using 
the Tissue Arrayer Mini-Core with TMA Designer2 soft-
ware (Alphelys). Three 1-mm-in-diameter tissue cores 
from the periphery of the FFPE primary tumours and 
lymph node metastases were transferred to TMA recipi-
ent blocks. TMA sections (4 μm) were cut and stained, 
and the tumours were reclassified into molecular subtypes. 
Human epidermal growth factor receptor 2 (HER2) was 
assessed using both CISH and IHC. Tumours with HER2/
chromosome enumeration probe 17 (CEP17) ratio ≥ 2 were 
defined as HER2 positive. When CISH was unsuccess-
ful, tumours with intense membranous staining (IHC 3+) 
in > 10% of tumour cells were considered HER2 positive.
Of the 1393 tumours, 909 were successfully reclassified 
into molecular subtypes [12]:Luminal A (ER and/or PR+ , 
HER2−, Ki67 < 15%), Luminal B (HER2−) (ER+ and/
or PR + , HER2−, Ki67 ≥ 15%), Luminal B (HER2+) 
(ER+ and/or PR+ , HER2+), HER2 type (ER− and PR− , 
HER2+), 5 negative phenotype (5NP; ER−, PR−, HER2−, 
CK5− and EGFR−) and Basal phenotype (BP; ER− , PR− , 
HER2 − , CK5+ and/or EGFR+) (Supplementary Fig. 1). 
From the time of diagnosis (baseline), patients were fol-
lowed until death from breast cancer, death from other 
causes or until December 31st, 2015. Individual information 
about adjuvant treatment is unavailable. However, due to age 
and/or time of diagnosis, few would have received chemo-
therapy. Some would have been treated with antihormonal 
treatment, but none qualified for trastuzumab. In the pre-
sent study, TMAs containing cores from tumours diagnosed 
mainly in the 1980s or later (n = 636) were included. Of 
these, 46 were excluded due to unsuccessful FISH (n = 30) 
or insufficient amounts of tumour tissue (n = 16). Thus, 590 
cases were suitable for MRPS23 and CEP17 copy number 
assessment. Of these, 192 had lymph node metastases, and 
lymph node tissue from 150 was available in TMAs. Due to 
unsuccessful FISH (n = 5) or insufficient amounts of tissue 
(n = 1), six were excluded. Hence, lymph node metastases 
from 144 cases were included.
Cohort 2 METABRIC
The METABRIC dataset includes a discovery dataset 
(n = 997), and a validation dataset (n = 995). The cohorts 
have previously been described in detail [13]. In the pre-
sent study, 1971 cases had available follow-up data and 
MRPS23 gene expression data from all primary breast 
tumours. Tumours of basal-like (n = 329), normal-like 
(n = 202) and unknown subtype (n = 6) were excluded 
from our analysis [3, 16, 17]. Thus, 1434 tumours were 
included. Patients with ER positive and/or lymph node 
negative tumours had not received chemotherapy, whereas 
patients with ER negative and lymph node positive 
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tumours did [13]. None of the HER2+ patients were 
treated with trastuzumab. To assess possible associa-
tions between gene expression levels and prognosis, cases 
were separated into quartiles. Prognosis for each quartile 
was analysed separately, and for dichotomization of gene 
expression values, patients with gene expression levels in 
the upper quartile were compared to all other cases.
MRPS23 FISH cohort 1
FISH was done according to the manufacturer’s guidelines 
using Dako Histology FISH Accessory Kit K 579911. 
After de-waxing and rehydration, TMA slides were 
boiled in a microwave oven (10 min) in Pre-Treatment 
Solution, cooled (15 min) and washed in Wash Buffer 
(2 × 3 min). Protein digestion was performed with Pep-
sin Solution at 37 °C (30 min), and then washed in Wash 
buffer (2 × 3 min). Dehydration was done in ethanol (70, 
80 and 95%) for 2 min at each concentration, and the 
slides were then air dried at room temperature for 15 min. 
FISH-custom probes for MRPS23 (3 μL, Empire Genom-
ics) and CEP17 (1 μL, Abbott/VYSIS) were mixed with 
hybridization buffer (9 μL, Empire Genomics) and applied 
to TMA slides. Coverslips were applied and sealed with 
coverslip sealant (Dako). Denaturation was performed at 
83 °C (3 min) followed by hybridization at 37 °C overnight 
in a DAKO Hybridizer. Post hybridization, TMA slides 
were rinsed in 0.4xSSC/0.3%NP-40 at 72 °C (2 min), and 
in 2xSSC/0.1%NP-40 at RT (15 s). Slides were air dried at 
37 °C (15 min). DAPI (15 μL, VYSIS. Abbott no 06J50-
001) was applied and the slides were coverslipped.
MRPS23 and CEP17 copy numbers were counted using a 
fluorescence microscope (Nikon Eclipse 90i). All available 
tissue cylinders from each case were examined, and MRPS23 
and CEP17 copy number in 20 well-preserved, non-over-
lapping tumour cell nuclei were recorded. Mean copy 
number of MRPS23/tumour cell and MRPS23/CEP17 ratio 
were estimated for each case. To assess the impact of mean 
MRPS23 copy number, cases were divided into three catego-
ries based on recent HER2 guidelines [18]: mean MRPS23 
copy number < 4; mean ≥ 4 < 6 and mean ≥ 6. To estimate 
the impact of gene/centromere ratio, cases were divided 
into two categories: MRPS23/CEP17 < 2 and MRPS23/
CEP17 ≥ 2. Finally, MRPS23 amplification (MRPS23+) was 
defined as mean MRPS23 copy number ≥ 6 and/or MRPS23/
CEP17 ratio ≥ 2. Cases with MRPS23 copy number < 6 and 
MRPS23/CEP17 ratio < 2 were defined as non-amplified 
(MRPS23−). To study the prognostic value of HER2 sta-
tus and MRPS23 status combined, cases were divided into 
four groups: MRPS23−/HER2−; MRPS23−/HER2+ ; 
MRPS23 + /HER2− and MRPS23+/HER2+. The REMARK 
criteria for tumour marker reporting were followed [19].
Statistical analyses
Pearson chi square tests were used to compare MRPS23 copy 
number status and MRPS23 gene expression levels in the 
primary tumours across patient and tumour characteristics. 
To compare copy number status in the primary tumours and 
their corresponding lymph node metastases, paired analyses 
were performed using McNemar’s and marginal homogene-
ity test.
For each category of MRPS23 copy number status and 
MRPS23/HER2 status in primary tumours, and for the 
MRPS23 gene expression categories, we estimated cumula-
tive incidence of death from breast cancer, with death from 
other causes as a competing event. We used Gray’s test to 
compare equality of cumulative incidence curves. Cox pro-
portional hazard models were used to estimate hazard ratios 
(HR) of breast cancer death with 95% confidence intervals 
(CI). In the Cox regression analyses, patients were cen-
sored at time of death from other causes. Where applicable, 
adjustments were made for age at baseline (≤ 49, 50–59, 
60–64, 65–69, 70–74, ≥ 75), histological grade (I–III), stage 
(I–IV), Ki67 status (< / ≥ 15%) and molecular subtype. We 
found no clear violations of proportionality in log-minus-log 
plots. Linear regression analyses were used for comparison 
of MRPS23 expression levels between different molecular 
subtypes.
All statistical tests were two-sided, and statistical signifi-
cance was assessed at 5% level. p-values between 5 and 10% 
were regarded borderline significant. All statistical analyses 




Mean age at diagnosis was 75.6 (SD 8.6, range 41–96) years 
and mean follow-up after diagnosis was 8.9 (SD 7.2) years. 
By the end of follow-up, 217 (37%) patients had died from 
breast cancer, and 318 (54%) had died from other causes 
(Table 1).
MRPS23 copy number status in primary tumours
When MRPS23 and CEP17 copy number alterations were 
present, a homogenous pattern was seen, with alterations 
in the majority of tumour cells. Three different pheno-
types were seen, tumours without copy number altera-
tions; tumours with MRPS23 and CEP17 copy number 
increase and tumours with MRPS23 copy number increase 
only (Fig. 1). In total, 29 of the primary tumours (5%) 
had mean MRPS23 copy number ≥ 4 < 6, 21 (4%) had 
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mean copy number ≥ 6 and 41 (7%) had MRPS23/CEP17 
ratio ≥ 2 (Table 1, Fig. 2). A total of 45 tumours (8%) 
were amplified (mean MRPS23 ≥ 6 and/or MRPS23/
CEP17 ≥ 2). Among cases with mean MRPS23 ≥ 6, 
four cases had MRPS23/CEP17 ratio < 2. Of cases with 
MRPS23/CEP17 ratio ≥ 2, 24 had mean MRPS23 < 6. 
MRPS23 copy number increase (mean ≥ 4) was found 
within all molecular subtypes except the 5NP (Table 1). 
Amplifications were found in all molecular subtypes 
except the 5NP and the BP. Amplifications were seen in 
30% of Luminal B (HER2+), 18% of HER2 type, 12% 
of Luminal B (HER2−), and 3% of Luminal A. Of the 
MRPS23 amplified tumours, 19 (42%) were HER2+ , 
compared to 58 (11%) of non-amplified tumours.
Copy number status in lymph node metastases
In total, 144 cases were examined for MRPS23 copy number 
status in their lymph node metastases (Table 2). There were 
no significant changes in MRPS23 copy number status in 
the lymph node metastases compared to the corresponding 
primary tumours. Among the pairs of primary tumours and 
lymph node metastases, 14 (10%) primary tumours were 
classified as MRPS23+ , and in 10 of these (71%), the cor-
responding lymph node metastases were also MRPS23+ . 
MRPS23 amplification was also identified in the lymph node 
metastases of two MRPS23-tumours.
MRPS23 copy number status and proliferation
Of the MRPS23 amplified tumours, 66% had high Ki67 
(≥ 15%), compared to 39% of the non-amplified tumours 
(Table 1). Mitotic counts were also higher in amplified 
tumours (borderline significance). Of the MRPS23 ampli-
fied tumours, 56% were grade III, compared to 31% of the 
non-amplified tumours. An association between MRPS23 
copy number increase and high Ki67, and high histological 
grade was also found when MRPS23 copy number status 
was defined by MRPS23 mean and MRPS23/CEP17 ratio 
(Table 1). In the lymph node metastases, MRPS23 amplifica-
tion was associated with high Ki67 (borderline significance, 
Table 3).
MRPS23 copy number status and prognosis
Mean MRPS23
The cumulative risk of death from breast cancer for cases 
with no copy number increase was 35% (95% CI 31–39) 
10  years after diagnosis (Table  4; Fig.  3a). The corre-
sponding risks for cases with mean copy number ≥ 4 < 6 
Fig. 1  Breast cancer cell nucleus with a two copies of MRPS23 and CEP17, b copy number increase of both MRPS23 and CEP17 and c copy 
number increase of MRPS23 without corresponding increase of CEP17
Fig. 2  Scatter plot of MRPS23 and CEP17 copy number in 590 breast 
cancer tumours
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and mean ≥ 6 was 34% (95% CI 20–55), and 43% (95% CI 
25–66), respectively. In the Cox regression analysis, there 
were no clear differences in the rates of death between cat-
egories. Adjustments for age, stage, grade, Ki67 or HER2 
status did not influence the results.
MRPS23/CEP17 ratio
After 10 years of follow-up, cases with MRPS23/CEP17 
ratio < 2 had a cumulative risk of death from breast cancer of 
30% (95% CI 27–34) (Table 4; Fig. 3b), whereas cases with 
ratio ≥ 2 had a corresponding risk of 41% (95% CI 30–58). 
When comparing rates of death from breast cancer, there 
was no clear difference between the two categories (HR 1.2, 
95% CI 0.8–2.0). Adjusting for age, stage, grade, Ki67 or 
HER2 status did not influence the results.
MRPS23 amplification status
After 10 years of follow-up, patients with MRPS23 amplified 
tumours had 40% (95% CI 27–56) cumulative risk of death 
from breast cancer, compared to 30% (95% CI 27–34) for 
patients without amplification (Table 4; Fig. 3c). The rates 
of death from breast cancer were similar for cases with and 
without amplification (HR 1.2, 95% CI 0.7–1.9). Separate 
adjustments for age, grade, histological grade, stage and 
HER2 status did not influence the results. Analysis of prog-
nosis was also done for Luminal A cases separately, and for 
all luminal subtypes combined. In these analyses, no clear 
differences in prognosis between MRPS23 amplified and 
non-amplified cases were seen (data not shown).
MRPS23/HER2− status
When tumours were reclassified into four categories based 
on MRPS23 and HER2 status, the highest risk of death was 
Table 2  MRPS23 status in primary tumours and lymph node metastases according to MRPS23/CEP17 ratio, mean MRPS23 and amplification 
status
a MRPS23/CEP17 < 2 and mean MRPS23 < 6
b MRPS23/CEP17 ≥ 2 and/or mean MRPS23 ≥ 6
Mean MRPS23/tumour cell, primary tumours Marginal 
homogeneity 
test < 4  ≥ 4, < 6  ≥ 6 Total
Mean MRPS23/tumour cell, lymph 
nodes
 < 4 125 (97) 4 (40) 1 (20) 130 p = 0.637
 ≥ 4, < 6 3 (2) 5 (50) 2 (40) 10
 ≥ 6 1 (1) 1 (10) 2 (40) 4
 Total 129 10 5 144
MRPS23/CEP17 ratio, primary tumours
 < 2  ≥ 2 Total McNemar test
MRPS23/CEP17 ratio, lymph nodes
 < 2 130 (99) 3 (23) 133 p = 0.625
 ≥ 2 1 (1) 10 (76) 11
 Total 131 13 144
Amplification status, primary tumours
MRPS23− MRPS23+ Total McNemar test
Amplification status, lymph nodes
 MRPS23−a 128 (98) 4 (29) 132 p = 0.688
 MRPS23+b 2 (2) 10 (71) 12
 Total 130 14 144
Table 3  MRPS23 amplification status and Ki67 levels in lymph nodes
a MRPS23/CEP17 < 2 and mean MRPS23 < 6
b MRPS23/CEP17 ≥ 2 and/or mean MRPS23 ≥ 6
MRPS23 amplification status, lymph node
MRPS23−a MRPS23+b Total χ2
Ki67, lymph node (%)
 Ki67 < 15% 69 (53%) 3 (25%) 72 p = 0.07
 Ki67 > 15% 62 (47%) 9 (75%) 71
 Total 131 12 143
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Table 4  Absolute and relative risk of death from breast cancer according to mean MRPS23/tumour cell, MRPS23/CEP17 ratio and amplification 
status
CI confidence interval, HR hazard ratio
a MRPS23/CEP17 < 2 and mean MRPS23 < 6
b MRPS23/CEP17 ≥ 2 and/or mean MRPS23 ≥ 6






 < 4  ≥ 4, < 6  ≥ 6  < 2  ≥ 2 MRPS23−a MRPS23+b
Cum. risk after 5 years (%) (95% CI) 21 (18–24) 24 (12–44) 38 (21–62) 21 (18–25) 29 (18–46) 21 (18–25) 29 (18–44)
Cum. risk after 10 years (%) (95% CI) 35 (31–39) 34 (20–55) 43 (25–66) 30 (27–34) 41 (30–58) 30 (27–34) 40 (27–56)
HR, unadjusted (95% CI) 1.0 0.9 (0.5–1.7) 1.5 (0.8–2.8) 1.0 1.2 (0.8–2.0) 1.0 1.2 (0.7–1.9)
HR adjusted for age (95% CI) 1.0 0.9 (0.5–1.7) 1.5 (0.8–2.8) 1.0 1.3 (0.8–2.1) 1.0 1.2 (0.7–1.9)
HR adjusted for stage (95% CI) 1.0 0.8 (0.4–1.5) 1.2 (0.6–2.4) 1.0 1.2 (0.7–1.9) 1.0 1.0 (0.6–1.7)
HR adjusted for grade (95% CI) 1.0 0.7 (0.4–1.4) 1.3 (0.7–2.4) 1.0 1.1 (0.7–1.7) 1.0 1.0 (0.6–1.6)
HR adjusted for Ki67 (95% CI) 1.0 0.7 (0.4–1.4) 1.1 (0.6–2.2) 1.0 1.0 (0.6–1.6) 1.0 1.0 (0.6–1.6)
HR adjusted for HER2 (95% CI) 1.0 0.9 (0.5–1.6) 1.2 (0.6–2.3) 1.0 1.0 (0.6–1.7) 1.0 1.0 (0.6–1.6)
Fig. 3  Cumulative incidence of death from breast cancer according to MRPS23 copy number status based on a mean MRPS23 copy number 
(p = 0.47), b MRPS23/CEP17 ratio (p = 0.29) and c MRPS23 amplification status (p = 0.39)
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found in the MRPS23+/HER2+ subtype (Table 5; Fig. 4). 
After 10 years of follow-up, patients with the MRPS23+/
HER2+ subtype had a cumulative risk of death from breast 
cancer of 63% (95% CI 42–83). The corresponding risk for 
the MRPS23−/HER2+ subtype was 47% (95% CI 36–61). 
The lowest risk of death was found in the MRPS23+ /HER2- 
subtype (23%, 95% CI 11–44). There were no clear differ-
ences in the rate of death from breast cancer between the 
MRPS23−/HER2+ and MRPS23+ /HER2+ subtypes (HR 
1.3, 95% CI 0.7–2.6). Separate analysis of prognosis was also 
done for all luminal cases, with similar results as for all cases 
combined (data not shown).
Cohort 2
MRPS23 expression according to molecular subtypes
In the METABRIC dataset, mean age at diagnosis was 61.1 
(SD 12.4, range 22–96) years, and mean follow-up after 
diagnosis was 8.1 (SD 4.9) years. Characteristics of the 
study population are given in Table 6. By the end of follow-
up, 506 (26%) patients had died from breast cancer, and 384 
(20%) had died from other causes.
High MRPS23 expression levels were associated with the 
Luminal B subtype (Fig. 5).
After 10 years of follow-up, cases with low MRPS23 
expression levels had a cumulative risk of death from breast 
cancer of 26% (95% CI 23–29%), compared to 24% (95% 
CI 20–30%) among cases with high MRPS23 expression 
(Cut-off upper quartile; Fig. 6, Table 7). Comparing the 
rates of death from breast cancer, there were no significant 
differences between cases with gene expression levels in the 
upper quartile compared to the rest (HR 0.9, 95% CI 0.7–1.2, 
Fig. 6, Table 7). Similar results were obtained when analysis 
of prognosis was done for each quartile separately. Adjust-
ments for age and histological grade did not influence the 
results.
Discussion
We identified MRPS23 amplification in 8% of primary 
tumours and 9% of lymph node metastases in a large pop-
ulation of Norwegian breast cancer patients. The highest 
proportion of amplified cases was found within Luminal B 
(HER2+), HER2 type and Luminal B (HER2−) tumours. 
None of the amplified tumours were triple negative (5NP/
BP). MRPS23 amplification was associated with high Ki67 
and high histological grade. No clear association between 
Table 5  Absolute and relative risk of dying from breast cancer according to HER2 status and amplification of MRPS23 
Cum. risk cumulative risk, CI confidence interval, HR hazard ratio
a MPR23− : MPRS23/CEP17 ratio < 2 and MRPS23 mean < 6
b MRPS23 + : MRPS23/CEP17 ratio ≥ 2 and/or MRPS23 mean ≥ 6
c HER2/CEP17 ratio ≥ 2 or intense membranous staining (IHC 3+) in > 10% of tumour cells
MRPS23−a/HER2− MRPS23−/HER2+c MRPS23+b/HER2− MRPS23+/HER2+
Cum. risk after 5 years (%) (95% CI) 18 (15–22) 44 (32–58) 12 (4–32) 53 (33–76)
Cum. risk after 10 years (%) (95% CI) 28 (25–32) 47 (36–61) 23 (11–44) 63 (42–83)
HR, unadjusted (95% CI) 1.0 1.6 (1.1–2.4) 0.6 (0.3–1.4) 2.6 (1.5–4.5)
HR adjusted for age (95% CI) 1.0 1.7 (1.1–2.5) 0.6 (0.3–1.4) 2.6 (1.5–4.8)
HR adjusted for grade (95% CI) 1.0 1.2 (0.8–1.8) 0.5 (0.2–1.1) 2.3 (1.3–4.0)
HR adjusted for stage (95% CI) 1.0 1.9 (1.3–2.8) 0.6 (0.3–1.4) 1.8 (1.0–3.3)
HR adjusted for Ki67 (95% CI) 1.0 1.3 (0.9–1.9) 0.5 (0.2–1.0) 2.2 (1.3–3.0)
HR adjusted for HER2 (95% CI) 1.0 1.6 (1.1–2.4) 0.6 (0.3–1.4) 2.6 (1.5–4.5)
Fig. 4  Cumulative incidence of death from breast cancer according to 
MRPS23 amplification status and HER2 status (p < 0.01)
82 Breast Cancer Research and Treatment (2020) 180:73–86
1 3
MRPS23 amplification and prognosis was seen. The pro-
portion of HER2 positive cases was higher among MRPS23 
amplified cases, compared to non-amplified. MRPS23+/
HER2+ had the poorest prognosis.
In the METABRIC dataset, Luminal B tumours had the 
highest level of MRPS23 gene expression. We found no sta-
tistically significant associations between MRPS23 expres-
sion levels and prognosis.
This study is based on a well-described cohort of breast 
cancer patients with long-term follow-up, and data from the 
METABRIC dataset. In the Norwegian cohort, the major-
ity of patients have been followed until death [12]. Since 
relapse may occur even decades after the primary diagnosis, 
long-term follow-up is of particular value in breast cancer 
research. Molecular subtyping was performed in the same 
laboratory, using the same algorithm and antibodies in all 
cases [12]. Using FISH, gene copy number can be assessed 
while observing the morphology of the tumour, ensuring 
that only invasive tumour cells were examined.
MRPS23 copy number in primary tumours and lymph 
node metastases was assessed in TMAs. In the primary 
tumours, tissue for TMAs was taken from the tumour periph-
ery. Previous studies have shown good correlation between 
TMAs and corresponding whole sections [20, 21]. Neverthe-
less, TMAs represent a small portion of each tumour, and, 
while copy number changes were observed throughout the 
tissue in amplified cases, intra tumour heterogeneity may not 
Table 6  Characteristics of Cohort 2 (METABRIC) (Normal-like and basal-like subtypes excluded from the analyses)
N number of patients, SD standard deviation, BC breast cancer
a Mean probe MRPS23 ≤ 8.31
b Mean probe MRPS23 > 8.31
Total study population Discovery cohort Validation cohort
Total Mean probe MRPS23 χ2
Quartile 1–3a Quartile  4b
N (%) 1434 1069 365 804 (56) 630 (44)
Mean age at diagnosis, years (SD) 63.2 (12.4) 63.6 (12.4) 62 (12.4) 62.3 (12.5) 64.3 (12.2)
Mean follow-up, years (SD) 8.3 (4.9) 8.5 (5) 7.8 (4.5) 8.1 (4.7) 8.5 (5.1)
Deaths from BC (%) 354 (25) 273 (25) 81 (22) 201 (25) 153 (24)
Deaths from other causes (%) 311 (22) 240 (22) 71 (19) 156 (19) 155 (25)
Histologic grade (%)
 I 139 (10) 116 (11) 23 (6)  < 0.001 61 (8) 78 (12)
 II 635 (44) 504 (47) 131 (36) 375 (47) 260 (41)
 III 598 (42) 392 (17) 206 (56) 368 (46) 230 (37)
 Unknown 62 (4) 57 (5) 5 (1) 0 62 (10)
Lymph node metastasis (%)
 Yes 684 (48) 491 (46) 193 (53) 0.030 383 (48) 301 (48)
 No 750 (52) 578 (54) 172 (47) 421 (52) 329 (52)
Tumour size (%)
 ≤ 2 cm 613 (43) 472 (44) 141 (39) 0.170 351 (42) 262 (42)
 > 2 cm, ≤ 5 cm 751 (52) 542 (51) 209 (57) 421 (52) 330 (53)
 > 5 cm 69 (5) 54 (5) 15 (4) 32 (4) 37 (6)
 Uncertain 1 (0) 1 (0) 0 0 1 (0)
Stage (%)
 I 104 (7) 84 (8) 20 (5) 0.075 0 104 (17)
 II 177 (12) 141 (13) 36 (10) 0 177 (28)
 III 27 (2) 20 (2) 7 (2) 0 27 (4)
 IV 1 (0) 0 1 (0) 0 1 (0)
 Unknown 1125 (78) 824 (77) 301 (82) 804 (100) 321 (50)
PAM50 subtype (%)
 Luminal A 709 (49) 606 (57) 103 (28) 445 (56) 255 (40)
 Luminal B 488 (34) 276 (26) 212 (58) 266 (33) 222 (35)
 HER2-type 237 (17) 187 (17) 50 (14)  < 0.001 84 (10) 153 (25)
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be captured. It would therefore be of interest to validate our 
findings in a study of whole sections.
There are no established guidelines as to how MRPS23 
amplification should be defined. According to HER2 ISH 
guidelines, both HER2 copy number and HER2/CEP17-ratio 
are taken into consideration [18]. MRPS23 and HER2 are 
both located on the long arm of chromosome 17 [4, 5, 22], 
and we chose to define MRPS23 amplification according to 
HER2 ISH guidelines, including both mean MRPS23 copy 
number and MRPS23/CEP17 ratio in our definition. Previ-
ous studies have shown a high frequency of abnormalities on 
chromosome 17, but rarely true polysomy [23]. The number 
of amplified cases was increased when including MRPS23/
CEP17 ratio in addition to mean MRPS23 in the definition 
of amplification. Hence, our definition may have led to over-
estimation of MRPS23 amplified cases. Nevertheless, we 
found that 8% of tumours were MRPS23 amplified, whereas 
20% and 33% of the tumours were amplified in the two 
datasets included in Gatza et al. In the latter two cohorts, 
only luminal (defined as non-basal) cases were included. 
When excluding the BP and 5NP in our in-house cohort, the 
proportion of amplified cases was still 8%. In accordance 
with other studies we found that amplification of MRPS23 
was associated with higher proliferation [3, 11]. However, 
contrary to others, we found no clear associations between 
MRPS23 copy number increase and a poorer prognosis 
[3]. Our study demonstrates the importance of validating 
biomarkers identified by high-throughput genomic analy-
ses. Validation analyses of single biomarkers with FISH, 
performed in FFPE tissue, indicate the marker’s prognostic 
potential when assessed in a routine diagnostic setting.
MRPS23 has previously been found to be amplified 
exclusively in highly proliferative luminal tumours [3]. In 
that study, PAM50 was used for molecular subtyping, and 
“luminal” was defined as all tumours that were not basal [3]. 
This definition of luminal was based on a study showing that 
breast tumours could be separated into two main groups, one 
group containing luminal and HER2-positive tumours and 
the other group comprising basal-like tumours [17]. In our 
study, cohort 1 was divided into six subtypes based on IHC 
and ISH. Although it has been shown that surrogate mark-
ers can be used for molecular subtyping [24–27], there is a 
discrepancy between molecular subtype defined by surrogate 
markers and subtypes defined by gene expression analyses 
[28, 29]. Nevertheless, similar to Gatza et al., we only found 
MRPS23 amplified cases among the non-basal tumours.
Contrary to others [3], we found no clear associations 
between MRPS23 amplification and prognosis in our 
cohort of Norwegian breast cancer patients. We used a 
different method for assessment of gene copy number in 
Fig. 5  MRPS23 gene expression according to molecular subtype in 
1971 patients from the METABRIC dataset
Fig. 6  Cumulative incidence of death from breast cancer according to MRPS23 gene expression divided into a quartiles 1–4 (p = 0.4), and b 
quartile 1–3 vs. quartile 4 (p = 0.6)
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our study (FISH), and different methodologies could partly 
explain the divergent results. Furthermore, the number of 
amplified cases was low in our study population, and the 
results must be interpreted with caution. Patient age in 
Cohort 1 is high, and the majority of patients were not 
given modern breast cancer treatment either due to their 
age at diagnosis or time of diagnosis [12]. This enables us 
to follow the near-natural course of disease after surgery. It 
would, however, be interesting to perform a MRPS23 FISH 
study in a cohort of younger patients treated according to 
current guidelines.
Interestingly, the MRPS23+ /HER2+ tumours had the 
poorest prognosis. HER2 is recognized as an important prog-
nostic marker in breast cancer, and interaction with MRPS23 
could potentially be of clinical importance. However, due 
to the low number of cases in some of the MRPS23/HER2 
categories, the results should be interpreted with caution.
We found no correlation between MRPS23 expression 
levels and prognosis in the METABRIC data set. In our anal-
yses of prognosis, we excluded basal-like and normal-like 
cases [3, 16]. A correlation between MRPS23 copy number 
status and gene expression has previously been found in the 
METABRIC dataset [3]. Since transcription is regulated by 
several mechanisms, good correlation between gene copy 
number and gene expression is infrequent [30–32]. Our anal-
yses show that MRPS23 expression levels were overlapping 
between the different molecular subtypes. Such overlap was 
also seen between the highly proliferative luminal tumours 
(Luminal B) and basal-like tumours, the latter shown to be 
non-amplified. This could possibly be due to other MRPS23 
up-regulating mechanisms, and potentially explain the lack 
of correlation between gene expression levels and prognosis 
in the METABRIC dataset.
Conclusion
Using FISH on a large cohort of breast cancer patients we 
found that MRPS23 amplification is associated with higher 
tumour cell proliferation. Amplifications were only found in 
luminal and HER2 type tumours. We found no association 
between MRPS23 amplification and prognosis. In the META-
BRIC dataset, gene expression levels were highest in Luminal 
B tumours. There was no correlation between MRPS23 expres-
sion and prognosis.
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